NTRK1 F589L

CI-VAR-00001126Explore in graph →CIViC 4510

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm6
LMNA::NTRK1 Fusion AND NTRK1 F589L	Entrectinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID11355 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the ent… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
LMNA::NTRK1 Fusion AND NTRK1 F589L	Larotrectinib	Predictive	D	Supports Resistance	3	accepted	EID11351 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Solid Neoplasm1
v::NTRK1 Fusion AND NTRK1 F589L	Larotrectinib	Predictive	A	Supports Resistance	2	submitted	EID11542 In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic